XTX Topco Ltd Has $1.26 Million Holdings in argenx SE (NASDAQ:ARGX)

XTX Topco Ltd decreased its position in argenx SE (NASDAQ:ARGX) by 59.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,040 shares of the company’s stock after selling 2,990 shares during the quarter. XTX Topco Ltd’s holdings in argenx were worth $1,255,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of ARGX. FMR LLC raised its position in argenx by 17.2% in the 4th quarter. FMR LLC now owns 5,618,222 shares of the company’s stock valued at $3,455,207,000 after buying an additional 824,750 shares during the last quarter. Clearbridge Investments LLC lifted its position in shares of argenx by 6.8% in the fourth quarter. Clearbridge Investments LLC now owns 629,828 shares of the company’s stock worth $387,344,000 after purchasing an additional 40,330 shares in the last quarter. Jennison Associates LLC lifted its position in shares of argenx by 27.0% in the fourth quarter. Jennison Associates LLC now owns 302,149 shares of the company’s stock worth $185,821,000 after purchasing an additional 64,183 shares in the last quarter. Lord Abbett & CO. LLC acquired a new position in argenx during the third quarter worth $88,339,000. Finally, Allspring Global Investments Holdings LLC grew its position in argenx by 38,152.3% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 144,211 shares of the company’s stock valued at $89,391,000 after purchasing an additional 143,834 shares in the last quarter. 60.32% of the stock is currently owned by institutional investors.

argenx Stock Up 4.4 %

Shares of argenx stock opened at $606.39 on Tuesday. The firm’s 50-day moving average price is $606.57 and its two-hundred day moving average price is $604.95. The company has a market capitalization of $36.84 billion, a price-to-earnings ratio of -689.08 and a beta of 0.60. argenx SE has a 12-month low of $352.77 and a 12-month high of $678.21.

argenx (NASDAQ:ARGX) last released its earnings results on Thursday, February 27th. The company reported $1.58 earnings per share for the quarter, topping the consensus estimate of $0.98 by $0.60. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. The firm had revenue of $761.22 million during the quarter, compared to analysts’ expectations of $678.52 million. On average, sell-side analysts expect that argenx SE will post 3.13 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the company. JMP Securities raised their price objective on argenx from $606.00 to $696.00 and gave the company a “market outperform” rating in a report on Tuesday, January 14th. Piper Sandler upped their price objective on argenx from $620.00 to $725.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 7th. HC Wainwright reissued a “buy” rating and issued a $720.00 target price on shares of argenx in a research note on Tuesday, April 8th. Oppenheimer upped their price target on shares of argenx from $675.00 to $704.00 and gave the stock an “outperform” rating in a research report on Friday, February 28th. Finally, Truist Financial reaffirmed a “buy” rating and issued a $700.00 target price (up from $660.00) on shares of argenx in a report on Tuesday, January 14th. Three analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $690.33.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.